BACKGROUND: Although treatment of latent tuberculosis infection (LTBI) is an essential component of tuberculosis (TB) control in countries such as the United States, it is not widely practiced in most TB-endemic countries. OBJECTIVE: To examine the practice of and adherence to LTBI treatment in a high-risk population in Brazil. DESIGN: We followed household contacts (HHCs) of patients hospitalized with pulmonary TB in Salvador, Brazil, for 6 months after they initiated LTBI treatment with isoniazid (INH). HHCs were asked to return to the hospital once a month for 6 months for follow-up visits and INH refills. RESULTS: Of 101 HHCs who initiated LTBI treatment, 54 (53.5%) completed the 6-month regimen. The risk of treatment non-completion was significantly higher in HHCs who reported side effects to INH (RR 2.69, 95%CI 1.3-5.8, P = 0.01), and in those who had to take two buses for a one-way trip to the hospital (RR 1.8, 95%CI 1.01-3.3, P = 0.04). Of the 101 HHCs, 29 (28.7%) did not return for any follow-up visits; these HHCs were significantly more likely to have a 2-bus commute to the hospital compared to HHCs who completed treatment (OR 20.69, 95%CI 2.1-208.4, P = 0.01). CONCLUSION: Nearly 50% of HHCs at high risk for developing TB completed a 6-month course of LTBI treatment. Completion of LTBI treatment was most affected by medication intolerance and commuting difficulties for follow-up visits.
BACKGROUND: Although treatment of latent tuberculosis infection (LTBI) is an essential component of tuberculosis (TB) control in countries such as the United States, it is not widely practiced in most TB-endemic countries. OBJECTIVE: To examine the practice of and adherence to LTBI treatment in a high-risk population in Brazil. DESIGN: We followed household contacts (HHCs) of patients hospitalized with pulmonary TB in Salvador, Brazil, for 6 months after they initiated LTBI treatment with isoniazid (INH). HHCs were asked to return to the hospital once a month for 6 months for follow-up visits and INH refills. RESULTS: Of 101 HHCs who initiated LTBI treatment, 54 (53.5%) completed the 6-month regimen. The risk of treatment non-completion was significantly higher in HHCs who reported side effects to INH (RR 2.69, 95%CI 1.3-5.8, P = 0.01), and in those who had to take two buses for a one-way trip to the hospital (RR 1.8, 95%CI 1.01-3.3, P = 0.04). Of the 101 HHCs, 29 (28.7%) did not return for any follow-up visits; these HHCs were significantly more likely to have a 2-bus commute to the hospital compared to HHCs who completed treatment (OR 20.69, 95%CI 2.1-208.4, P = 0.01). CONCLUSION: Nearly 50% of HHCs at high risk for developing TB completed a 6-month course of LTBI treatment. Completion of LTBI treatment was most affected by medication intolerance and commuting difficulties for follow-up visits.
Authors: Merrin E Rutherford; Rovina Ruslami; Melissa Anselmo; Bachti Alisjahbana; Neti Yulianti; Hedy Sampurno; Reinout van Crevel; Philip C Hill Journal: Bull World Health Organ Date: 2013-09-10 Impact factor: 9.408
Authors: Neela D Goswami; Lara Beth Gadkowski; Carla Piedrahita; Deborah Bissette; Marshall Alex Ahearn; Michela L M Blain; Truls Østbye; Jussi Saukkonen; Jason E Stout Journal: BMC Public Health Date: 2012-06-21 Impact factor: 3.295
Authors: Merrin E Rutherford; Rovina Ruslami; Winni Maharani; Indria Yulita; Sarah Lovell; Reinout Van Crevel; Bachti Alisjahbana; Philip C Hill Journal: BMC Res Notes Date: 2012-01-06
Authors: Mai T Pho; Soumya Swaminathan; Nagalingeswaran Kumarasamy; Elena Losina; C Ponnuraja; Lauren M Uhler; Callie A Scott; Kenneth H Mayer; Kenneth A Freedberg; Rochelle P Walensky Journal: PLoS One Date: 2012-04-30 Impact factor: 3.240
Authors: Barbara Reis-Santos; Rodrigo Locatelli; Bernardo L Horta; Eduardo Faerstein; Mauro N Sanchez; Lee W Riley; Ethel Leonor Maciel Journal: PLoS One Date: 2013-04-24 Impact factor: 3.240